Zura Bio

ZURA · NASDAQ

$4.00+$0.19 (+4.99%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.81

ZURA analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $19.21 (+380.2% upside)

Low: $11.11
Now: $4.00
High: $27.30

Upgrades and downgrades

The latest rating actions, newest first

ZURA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wedbush	Aug 12, 2026	Maintains	Outperform	$15.00 → $22.00	40%
Guggenheim	Aug 12, 2026	Maintains	Buy	$15.00 → $20.00	49%
William Blair	Jul 8, 2026	Initiates	Outperform	—	35%
Wedbush	Jul 1, 2026	Maintains	Outperform	$15.00	40%
Chardan Capital	Mar 23, 2026	Maintains	Buy	$10.00 → $11.00	54%
Oppenheimer	Mar 20, 2026	Maintains	Outperform	$16.00 → $15.00	52%
Wedbush	Feb 9, 2026	Initiates	Outperform	$15.00	40%
Chardan Capital	Nov 14, 2025	Maintains	Buy	$10.00	54%
Clear Street	Nov 13, 2025	Initiates	Buy	$18.00	38%

The case for and against

Updated Oct 21, 2026

Bull case

Zura Bio is positioned as a compelling clinical-stage biotech because its lead asset tibulizumab targets two complementary inflammatory pathways, IL-17A and BAFF, that could outperform the apparent efficacy ceiling of monotherapies in hidradenitis suppurativa and deliver differentiated benefit in PMR and SSc. The company’s near-term catalyst path is unusually clear, with the TibuSHIELD HS readout expected in late Oct./early Nov. after enrollment exceeded target at N=247 versus N=225, plus a 4Q26 HS readout, a 1H27 SSc readout, and a YE26 PMR study start. Financially, Zura exited 2Q26 with $205.1MM in cash, a $2/sh cash position, and a runway through at least YE28, supporting the positive risk/reward view.

Bear case

Zura Bio is viewed negatively because its valuation depends heavily on tibulizumab and other early-stage assets that may fail to demonstrate efficacy or acceptable safety, any of which could halt development or trigger regulatory setbacks. Competitive pressure also appears substantial, as JAK inhibitors such as Xeljanz and Olumiant could limit adoption even if approved, while their black box warnings suggest the broader autoimmune market remains constrained by safety concerns and treatment sequencing. The company also faces classic biotech financing risk because, until cash flow positive, it may need additional public or private capital, and manufacturing or shipment issues could further impair the path to sales estimates.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.